Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"VectorBuilder","sponsor":"Lantu Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VectorBuilder Supports First Gene Therapy Trial for Menkes Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","amount":"$56.1 million","upfrontCash":"Undisclosed","newsHeadline":"VectorBuilder Secures CNY410M in Series C Round","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Stand Up Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stand Up Therapeutics Signed with VectorBuilder for World's First Gene Therapy Supply for Paraplegia Patient","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by VectorBuilder

    Menu

    VectorBuilder

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              VectorBuilder

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stand Up Therapeutics Signed with VectorBuilder for World's First Gene Therapy Supply for Paraplegia Patient

              Details:

              STUP-001 (AAV-based gene therapy), the innovative GT medication, unties the knot for spinal cord injured patient through motor sensory neuron reprogramming technology. Cell fate conversion using virus transduction system is of great interest in the field of Gene Therapy.

              Lead Product(s): AAV-Based Gene Therapy

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: STUP-001

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Stand Up Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement December 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              VectorBuilder

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              VectorBuilder Secures CNY410M in Series C Round

              Details:

              The company intends to use the funds to promote the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines.

              Lead Product(s): Undisclosed

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Legend Capital

              Deal Size: $56.1 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing October 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              VectorBuilder

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              VectorBuilder Supports First Gene Therapy Trial for Menkes Disease

              Details:

              The adeno-associated virus (AAV) based drug, LTGT06, was developed by Lantu with crucial support from VectorBuilder. The trial subject was a three-year-old boy whose father gained worldwide attention for not giving up on his son.

              Lead Product(s): LTGT06

              Therapeutic Area: Genetic Disease Product Name: LTGT06

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Lantu Biopharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership August 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY